

## Review title

Impact of physical and psychological factors on the health related quality of life in adult patients with liver cirrhosis: a systematic review of quantitative evidence protocol.

## Reviewers

<sup>1</sup> Ms Suzanne Polis, Registered Nurse (BN, MPH [Research])

<sup>2</sup> Professor Ritin Fernandez, Professor of Nursing (BSc [Nursing], MN [Critical Care], PhD)

1. St George Hospital
2. Centre for Evidence based Initiatives in Health Care: an Affiliate Centre of the Joanna Briggs Institute
3. School of Nursing and Midwifery, University of Wollongong

## Review question/objective

The objective of this review is to identify the impact of physical and psychological factors on the health related quality of life in adult patients diagnosed with liver cirrhosis.

## Background

All chronic liver diseases stimulate a degree of repetitive hepatocyte injury that alters the normal liver architecture and ends in cirrhosis <sup>1</sup>. Liver cirrhosis and hepatocellular carcinoma secondary to liver cirrhosis are a major public health burden reporting increasing mortality and morbidity in Australia and globally <sup>2-6</sup>. The four leading causes of cirrhosis are harmful alcohol consumption, viral hepatitis B and C and metabolic syndromes related to non-alcoholic fatty liver disease and obesity <sup>7-9</sup>.

A cirrhotic liver is characterized by the presence of regenerative nodules surrounded by fibrous bands <sup>1,10</sup> that inhibit the passing of molecules between blood and functional units of liver hepatocytes leading to liver dysfunction <sup>10,11</sup>. In addition, the presence of fibrous bands disrupt the normal vascular architecture increasing resistance within the liver sinusoids and contributing to increased portal vein pressure <sup>10,12</sup>.

Early stages of cirrhosis is referred to as compensated liver disease with no reported symptoms or evidence of impaired liver function <sup>12,13</sup>. However, mortality rate, signs and symptoms of liver failure increase as the severity of cirrhosis increase <sup>13</sup>. Transition from compensated to decompensated cirrhosis is marked by one or more physiological changes. The physiological changes include increased portal vein pressure, impaired synthetic function, electrolyte imbalance and malnourishment <sup>13</sup>. These physiological changes trigger the development of physical signs and symptoms and impact on the psychological wellbeing of the individual living with cirrhosis. The physical signs and symptoms include oesophageal varices, ascites, hepatic encephalopathy, jaundice, irregular sleep patterns,

muscle cramps, pruritus, fatigue, impaired mobility, breathlessness, abdominal discomfort, gastrointestinal symptoms, change of body image and pitting oedema<sup>14-17</sup>. Psychological symptoms include stress, depression, and anxiety<sup>18,19</sup>.

Living with liver cirrhosis has a marked impact on the quality of life of the individual. Health related quality of life (HRQOL) is the individuals perception of their physical, cognitive, emotional, and social functioning<sup>20</sup>. Studies report that physiological, physical and psychological factors affect the quality of life of patients with cirrhosis which can be problematic and debilitating<sup>18,21-28</sup>. There is strong evidence which indicates that disease severity is associated with an impairment of the patients' HRQOL<sup>15,18,22,24-26,29</sup>. For example, gross ascites causes abdominal discomfort, breathlessness, increased stress and anxiety related to body image, immobility and an increased likelihood of falls. In addition, the management of ascites involves frequent invasive procedures, an increase in pill burden and implementation of dietary restrictions all of which impact on HRQOL<sup>26</sup>.

Despite the clear relationship between HRQOL and severity of disease, there has been no systematic review undertaken to determine the physical, psychological and physiological factors that affect the HRQOL of patients with liver cirrhosis. This systematic review will therefore identify the best available evidence related to the impact of physical, psychological and physiological factors on the health related quality of life in adult patients with liver cirrhosis. The results of the review will increase clinician's knowledge, and highlight areas of clinical management that may require additional strategies and treatment plans to improve symptom relief and HRQOL.

## **Inclusion criteria**

### **Types of participants**

This review will consider studies that include adult patients, aged 18 years clinically diagnosed with compensated or decompensated liver cirrhosis. Studies investigating non-liver disease related cirrhosis, the use of herbal medications, pre and post liver transplant and/or hepatocellular carcinoma patients, include non-cirrhotic patients, include inpatient data, non-liver related co-morbidities, patients undergoing interferon therapies and clinical trial studies investigating the use of medications or alternate interventions on HRQOL will be excluded.

### **Types of intervention(s)/phenomena of interest**

Studies will be included if they have assessed the following physical and psychological factors on the HRQOL of patients. The physical factors will include but not limited to oesophageal varices ascites, hepatic encephalopathy, jaundice, irregular sleep patterns, muscle cramps, pruritus, fatigue, impaired mobility, breathlessness, abdominal discomfort, gastrointestinal symptoms, change of body image and pitting oedema. The psychological factors include stress, depression, and anxiety.

### **Types of outcomes**

Studies will be included if they have objectively measured quality of life, including measuring any of the following domains: Physical wellbeing, Social and family wellbeing, Emotional and psychological wellbeing and Functional wellbeing.

Studies will be included if quality of life has been measured using objective scales including but not limited to: Liver Disease Quality of Life 1.0 (LDQOL), Short Form 36 Profile (SF-36), Chronic Liver

Disease Questionnaire (CLDQ), Liver disease symptom index 2.0 (LDSI 2.0), Hepatitis quality of life questionnaire.

### **Types of studies**

This review will consider experimental study designs including randomised controlled trials, non-randomized controlled trials, prospective and retrospective cohort studies and descriptive studies for inclusion.

## **Search strategy**

The search strategy aims to find both published and unpublished studies. A three-step search strategy will be utilised in this review. An initial limited search of Cochrane review, MEDLINE and CINAHL will be undertaken followed by analysis of the text words contained in the title and abstract, and of the index terms used to describe article. A second search using all identified keywords and index terms will then be undertaken across all included databases. Thirdly the reference list of all identified reports and articles will be searched for additional studies. Studies published in the English language will be considered for inclusion in this review. Studies published from 1990 will be considered for inclusion in the review as new interventions and medical management substantially improved overall liver function and health outcomes.

The databases to be searched include: Medline, CINAHL, Embase, Pubmed, CENTRAL, Scopus

The search for unpublished studies will include: ProQuest Dissertation & Theses and MedNar

Initial key words to be used will be:

Cirrhosis

Quality of life

Health related quality of life

Encephalopathy

Ascites

Portal hypertension

Oesophageal varices

Muscle cramps

Cognitive impairment

Sleep disturbance

Pitting oedema

Depression

Pruritus

Health distress

Activity

Memory

Hypo-natraemia

Hypo-albuminemia

Anxiety

Alexithymia

Abdominal bloating

Abdominal pain

Diarrhoea

Faecal incontinence

## **Assessment of methodological quality**

Quantitative papers selected for retrieval will be assessed by two independent reviewers for methodological validity prior to inclusion in the review using standardised critical appraisal instruments from the Joanna Briggs Institute Meta Analysis of Statistics Assessment and Review Instrument (JBI-MAStARI) (Appendix I). Any disagreements that arise between the reviewers will be resolved through discussion, or with a third reviewer.

## **Data collection**

Quantitative data will be extracted for papers included in the review using the standardised data extraction tool from JBI-MAStARI (Appendix II). The data extracted will include specific details about the interventions, populations, study methods and outcomes of significance to the review question and specific objectives.

## **Data synthesis**

Quantitative papers will, where possible be pooled in statistical meta-analysis using JBI-MAStARI. All results will be subject to double data entry. Effect sizes expressed as odds ratio (for categorical data) and weighted means differences (for continuous data) and their 95% confidence intervals will be calculated for analysis. Heterogeneity will be assessed statistically using the standard chi-square and also explored using sub-group analyses based on different quantitative study designs included in this review. Where statistical pooling is not possible the findings will be presented in narrative form including tables and figures to aid in data presentation where appropriate.

## **Conflicts of interest**

No conflicts of interest can be identified or foreseen in relation to this proposed systematic review.

## **Acknowledgements**

## References

1. Schuppan D, Afdhal NH. Liver cirrhosis. *Lancet* 2008;371:838-51.
2. Gidding HF, Amin J, Dore GJ, Law MG. Hospitalization rates associated with hepatitis B and HIV co-infection, age and sex in a population-based cohort of people diagnosed with hepatitis C. *Epidemiol Infect* 2011;139:1151-8.
3. Gidding HF, Amin J, Dore GJ, Ward K, Law MG. Hospital-related morbidity in people notified with hepatitis C: a population-based record linkage study in New South Wales, Australia. *Journal of hepatology* 2010;53:43-9.
4. Thein HH, Walter SR, Gidding HF, et al. Trends in incidence of hepatocellular carcinoma after diagnosis of hepatitis B or C infection: a population-based cohort study, 1992-2007. *J Viral Hepat* 2011;18:e232-41.
5. Gidding HF, Dore GJ, Amin J, Law MG. Trends in all cause and viral liver disease-related hospitalizations in people with hepatitis B or C: a population-based linkage study. *BMC Public Health* 2011;11:52.
6. Amin J, Gidding H, Gilbert G, et al. Hepatitis C prevalence--a nationwide serosurvey. *Commun Dis Intell* 2004;28:517-21.
7. Neff GW, Duncan CW, Schiff ER. The current economic burden of cirrhosis. *Gastroenterology & hepatology* 2011;7:661-71.
8. Leon DA, McCambridge J. Liver cirrhosis mortality rates in Britain from 1950 to 2002: an analysis of routine data. *The Lancet*;367:52-6.
9. Perz JF, Armstrong GL, Farrington LA, Hutin YJF, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. *Journal of hepatology* 2006;45:529-38.
10. Hill C. Anatomy and physiology. In: Sargent S, ed. *Liver Diseases: An essential guide ofr nurses and health care professionals*. United Kingdom: Wiley Blackwell; 2009.
11. Lefton HB, Rosa A, Cohen M. Diagnosis and Epidemiology of Cirrhosis. *Medical Clinics of North America* 2009;93:787-99.
12. Wong T. Portal hypertension. In: Sargent S, ed. *Liver Diseases: An essential guide for nurses and health care professionals*. Wiley -Blackwell; 2009:46-58.
13. D'Amico GT, G. Pagliaro, L. Natural history and prognostic indicators of survival in cirrhosis: A systematic review of 118 studies. *Journal of hepatology* 2006;44:217-31.

14. Amico G, Garcia-Tsao, G, Pagliaro, L. Natural history and prognostic indicators of survival in cirrhosis: A systematic review of 118 studies. *Journal of hepatology* 2006;44:217-31.
15. Fritz E, Hammer J. Gastrointestinal symptoms in patients with liver cirrhosis are linked to impaired quality of life and psychological distress. *European journal of gastroenterology & hepatology* 2009;21:460-5.
16. Tsai LH, Lin CM, Chiang SC, Chen CL, Lan SJ, See LC. Symptoms and distress among patients with liver cirrhosis but without hepatocellular carcinoma in Taiwan. *Gastroenterology nursing : the official journal of the Society of Gastroenterology Nurses and Associates* 2014;37:49-59.
17. Sogolow ED, Lasker JN, Short LM. Fatigue as a major predictor of quality of life in women with autoimmune liver disease: the case of primary biliary cirrhosis. *Women's health issues : official publication of the Jacobs Institute of Women's Health* 2008;18:336-42.
18. Nardelli S, Pentassuglio I, Pasquale C, et al. Depression, anxiety and alexithymia symptoms are major determinants of health related quality of life (HRQoL) in cirrhotic patients. *Metabolic brain disease* 2013;28:239-43.
19. Vaughn-Sandler V, Sherman C, Aronsohn A, Volk ML. Consequences of perceived stigma among patients with cirrhosis. *Digestive diseases and sciences* 2014;59:681-6.
20. Ferrans CE, Zerwic JJ, Wilbur JE, Larson JL. Conceptual Model of Health-Related Quality of Life. *Journal of Nursing Scholarship* 2005;37:336-42.
21. Kondo Y, Yoshida H, Tateishi R, et al. Health-related quality of life of chronic liver disease patients with and without hepatocellular carcinoma. *Journal of gastroenterology and hepatology* 2007;22:197-203.
22. Les I, Doval E, Flavia M, et al. Quality of life in cirrhosis is related to potentially treatable factors. *European journal of gastroenterology & hepatology* 2010;22:221-7.
23. Loria A, Escheik C, Gerber NL, Younossi ZM. Quality of life in cirrhosis. *Current gastroenterology reports* 2013;15:301.
24. Marchesini GB, G. Amodio, P. et al and the Italian study group for quality of life in cirrhosis. Factors associated with poor health-related quality of life of patients with cirrhosis. *Gastroenterology* 2001;120:170-8.
25. Roman E, Cordoba J, Torrens M, Guarner C, Soriano G. Falls and cognitive dysfunction impair health-related quality of life in patients with cirrhosis. *European journal of gastroenterology & hepatology* 2013;25:77-84.
26. Sola E, Watson H, Graupera I, et al. Factors related to quality of life in patients with cirrhosis and ascites: relevance of serum sodium concentration and leg edema. *Journal of hepatology* 2012;57:1199-206.

27. Sumskiene J, Sumskas L, Petrauskas D, Kupcinskas L. Disease-specific health-related quality of life and its determinants in liver cirrhosis patients in Lithuania. *World journal of gastroenterology* : WJG 2006;12:7792-7.

28. Svirtlih N, Pavic S, Terzic D, et al. Reduced quality of life in patients with chronic viral liver disease as assessed by SF12 questionnaire. *Journal of gastrointestinal and liver diseases* : JGLD 2008;17:405-9.

29. Samanta J, Dhiman RK, Khatri A, et al. Correlation between degree and quality of sleep disturbance and the level of neuropsychiatric impairment in patients with liver cirrhosis. *Metabolic brain disease* 2013;28:249-59.

## Appendix I: Appraisal instruments

### MAStARI Appraisal instrument

#### JBI Critical Appraisal Checklist for Randomised Control / Pseudo-randomised Trial

Reviewer ..... Date .....

Author ..... Year ..... Record Number .....

	Yes	No	Unclear	Not Applicable
1. Was the assignment to treatment groups truly random?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
2. Were participants blinded to treatment allocation?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
3. Was allocation to treatment groups concealed from the allocator?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
4. Were the outcomes of people who withdrew described and included in the analysis?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
5. Were those assessing outcomes blind to the treatment allocation?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
6. Were the control and treatment groups comparable at entry?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
7. Were groups treated identically other than for the named interventions	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
8. Were outcomes measured in the same way for all groups?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
9. Were outcomes measured in a reliable way?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
10. Was appropriate statistical analysis used?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

Overall appraisal:    Include                     Exclude                     Seek further info.

Comments (Including reason for exclusion)

---



---



---



### JBI Critical Appraisal Checklist for Descriptive / Case Series

Reviewer ..... Date .....

Author ..... Year ..... Record Number .....

	Yes	No	Unclear	Not Applicable
1. Was study based on a random or pseudo-random sample?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
2. Were the criteria for inclusion in the sample clearly defined?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
3. Were confounding factors identified and strategies to deal with them stated?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
4. Were outcomes assessed using objective criteria?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
5. If comparisons are being made, was there sufficient descriptions of the groups?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
6. Was follow up carried out over a sufficient time period?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
7. Were the outcomes of people who withdrew described and included in the analysis?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
8. Were outcomes measured in a reliable way?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
9. Was appropriate statistical analysis used?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

Overall appraisal:    Include                     Exclude                     Seek further info

Comments (Including reason for exclusion)

---

---

---

### JBI Critical Appraisal Checklist for Comparable Cohort/ Case Control

Reviewer ..... Date .....

Author ..... Year ..... Record Number .....

	Yes	No	Unclear	Not Applicable
1. Is sample representative of patients in the population as a whole?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
2. Are the patients at a similar point in the course of their condition/illness?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
3. Has bias been minimised in relation to selection of cases and of controls?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
4. Are confounding factors identified and strategies to deal with them stated?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
5. Are outcomes assessed using objective criteria?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
6. Was follow up carried out over a sufficient time period?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
7. Were the outcomes of people who withdrew described and included in the analysis?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
8. Were outcomes measured in a reliable way?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
9. Was appropriate statistical analysis used?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

Overall appraisal:    Include                     Exclude                     Seek further info.

Comments (Including reason for exclusion)

---

---

---

## Appendix II: Data extraction instruments

### MAStARI data extraction instrument

#### **JBI Data Extraction Form for Experimental / Observational Studies**

Reviewer ..... Date .....

Author ..... Year .....

Journal ..... Record Number .....

#### **Study Method**

RCT                       Quasi-RCT                       Longitudinal

Retrospective                       Observational                       Other

#### **Participants**

Setting

---

Population

---

#### **Sample size**

Group A \_\_\_\_\_ Group B \_\_\_\_\_

#### **Interventions**

Intervention A

---

Intervention B

---

Authors Conclusions:

---

---

---

Reviewers Conclusions:

---

---

---

**Study results**

**Dichotomous data**

<b>Outcome</b>	<b>Intervention ( ) number / total number</b>	<b>Intervention ( ) number / total number</b>

**Continuous data**

<b>Outcome</b>	<b>Intervention ( ) number / total number</b>	<b>Intervention ( ) number / total number</b>